Cost-effectiveness of daratumumab plus bortezomib and dexamethasone versus bortezomib plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy

An analysis of the Castor trial

Maiese, E. M., Graham, CN., Hawe, E., Le Moine, J-G., Abraham, I., & Senbetta, M. (2017). Cost-effectiveness of daratumumab plus bortezomib and dexamethasone versus bortezomib plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy: An analysis of the Castor trial. Blood, 130.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Article

Long-term effects of a diet supplement containing Cannabis sativa oil and Boswellia serrata in dogs with osteoarthritis following physiotherapy treatments
Article

Use of a web-based portal to return normal individual research results in Early Check
Article

The importance of quality data to track global progress in addressing stillbirths and neonatal mortality